Table 4.
Unadjusted and fully adjusted HRs (95% CIs) for all-cause mortality seen in sensitivity analyses I, II, and III
| Sensitivity analysis I | Sensitivity analysis II | Sensitivity analysis IIIa | ||||
|---|---|---|---|---|---|---|
| HgbMs considered | First per month | All measured | First per month | |||
| No. required HgbMs | 3 | 6 | 6 | |||
| N | 7474 | 6644 | 6644 | |||
| HR (95% CI) | Unadjusted | Fully adjustedb | Unadjusted | Fully adjustedb | Unadjusted | Fully adjustedc |
| Hgb residual SD (per g/dl) | 0.94 (0.80 to 1.10) | 1.11 (0.92 to 1.33) | 0.99 (0.81 to 1.21) | 1.16 (0.94 to 1.44) | 1.31 (1.05 to 1.64) | 1.17 (0.93 to 1.49) |
| Mean Hgb (per g/dl) | 0.67 (0.62 to 0.72) | 0.76 (0.68 to 0.86) | 0.70 (0.64 to 0.77) | 0.76 (0.67 to 0.85) | 0.72 (0.65 to 0.79) | 0.75 (0.67 to 0.85) |
| Hgb slope (per g/dl per month) | 0.62 (0.51 to 0.76) | 0.97 (0.77 to 1.24) | 0.70 (0.56 to 0.89) | 0.97 (0.75 to 1.26) | NR | NR |
HgbMs, hemoglobin measurements; NR, not reported.
In sensitivity analysis III, Hgb parameters were calculated using regression models that included an additional, quadratic term for time.
Covariates included other Hgb variables, age, sex, race, BMI, comorbidities (diabetes, hypertension, arterial disease (coronary and/or cerebrovascular and/or peripheral vascular disease), cancer, and congestive heart failure), laboratory results (serum creatinine, phosphate, albumin, and ekT/V averaged over days 90-180), and cumulative 6-month intravenous iron and erythropoietin doses.
Adjusted for covariates listed as well as the quadratic representation of hemoglobin over time.